How much funding has Bright Peak Therapeutics raised?

Bright Peak Therapeutics has raised $232.0M in total funding, most recently a Series C round.

Who are Bright Peak Therapeutics's investors?

Bright Peak Therapeutics's investors include Jerel Davis, RA Capital Management, Johnson & Johnson Innovation, Fidelity Management, Venrock, KB Investment.

When was Bright Peak Therapeutics founded?

Bright Peak Therapeutics was founded in 2017.

Where is Bright Peak Therapeutics headquartered?

Bright Peak Therapeutics is headquartered in Del Mar, California, United States.

What industry is Bright Peak Therapeutics in?

Bright Peak Therapeutics operates in Biotech, Healthcare.

How many employees does Bright Peak Therapeutics have?

Bright Peak Therapeutics has 51-200 employees.

Bright Peak Therapeutics

Next-generation multifunctional precision immunotherapies

Del Mar, United States · Founded 2017 · $232.0M raised

Biotech

Healthcare

Headquarters: Del Mar, California
Employees: 51–200
Founded: 2017
Business Model: B2B

Website: brightpeaktx.com
Total Funding: $232.0M
Last Round: $90.0M Series CJun 2024
Rounds: 3

About

Bright Peak Therapeutics is a biotechnology company advancing next-generation multifunctional precision immunotherapies. The company uses world-class protein engineering capabilities to create multi-functional PD-1 inhibitors, integrating both novel and validated mechanisms. Co-founded in 2017 by Vijaya Pattabiraman and Jeffrey Bode, Bright Peak is backed by leading healthcare investors including Versant Ventures, Fidelity Management & Research Company, RA Capital Management, Qatar Investment Authority, Invus, Alexandria Venture Investments, Venrock, and KB Investment. The company is co-located in Basel, Switzerland and San Diego (Del Mar), California, with a dual focus on cancer and autoimmune diseases.

Summary

Bright Peak Therapeutics is a Biotech company based in Del Mar, United States, founded in 2017. It has raised $232.0M in total across 3 rounds, most recently a $90.0M Series C round in Jun 2024. Investors include Jerel Davis, RA Capital Management and Johnson & Johnson Innovation.